Cardiovascular (CV) risk prediction and CV biomarkers in renal transplant recipients treated with belatacept compared to calcineurin inhibitors (CNI).Open randomized 12 month study.

ppsala University Hospital, MHT, Department of Nephrology0 个研究点目标入组 110 人开始时间: 2014年4月7日最近更新: 2018年12月4日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 110

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Signed Written Informed Consent
•2. Target Population:
•2.a Renal transplant recipients of living donor or deceased donor kidney transplant.
•2.b Stable renal graft with no need for exploratory examination (eGFR >20 ml/min)
•2.c Tacrolimus or CsA (Cyclosporine A) standard treatment since transplantation
•2.d 3 – 60 months post-transplantation at randomization
•3. Age and Sex:
•3.a Men and women, aged 18 to 80 years, both inclusive.
•3.b Women of childbearing potential (WOCBP) must be using adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the last dose of study drug to minimize the risk of pregnancy. WOCBP include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who is not postmenopausal. Post-menopause is defined as:
•Amenorrhea that has lasted for >= 12 consecutive months without another cause, or
•For women with irregular menstrual periods who are taking hormone replacement therapy (HRT), a documented serum follicle-stimulating hormone (FSH) level of greater than 35 mIU/mL. Women who are using oral contraceptives, other hormonal
•contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine
•device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or who are practicing abstinence or where their partner is sterile (e.g. vasectomy) should be considered to be of childbearing potential.
•WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours before the start of the investigational product (belatacept).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 70
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 40

排除标准

•1. Sex and Reproductive Status
•1.a WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of study drug.
•1.b Women who are pregnant or breastfeeding.
•1.c Women with a positive pregnancy test.
•2. Target Disease Exceptions
•Subjects who are EBV IgG negative or have unknown IgG status for EBV.
•3. Medical History and Concurrent Diseases
•3.a De novo or recurrent underlying renal disease that, in the Investigator's opinion, could adversely influence the current allograft
•3.b History of vascular or antibody-mediated rejection in the present transplant
•3.c Ongoing serious infections, as per Investigator's opinion
•3.d Signs of post-transplant lymphoproliferative disorder
•3.e History of tuberculosis. If the patient has a history of active TB or a history of latent untreated TB, the patient must be excluded from the study. If the patient has a history of latent treated TB, the patient can be included
•3.f Signs of malignancy. Exceptions are BCC/SCC or non-malignant melanoma
•3.g History of malignancy, unless subject has been considered to have fully recovered from malignancy more than 1 year ago, without any signs of relapse
•3.h Life expectancy < 3 years at the time of randomization
•4. Allergies and Adverse Drug Reactions
•4.a Hypersensitivity to belatacept
•4.b Previous/ongoing use of rituximab in connection with the current transplant.
•5. Other Exclusion Criteria
•5.a Prisoners, or subjects who are involuntarily incarcerated.
•5.b Subjects who are compulsorily detained for treatm

研究者

发起方

ppsala University Hospital, MHT, Department of Nephrology

相似试验

进行中（未招募）

1 期

Cardiovascular (CV) risk prediction and CV biomarkers in renal transplant recipients treated with belatacept compared to calcineurin inhibitors (CNI)Open randomized 12 month study

EUCTR2013-001178-20-SEppsala University Hospital, MHT, Department of Nephrology105

进行中（未招募）

1 期

Does conversion to Nulojix reduce the risk of cardiovascular disease in kidney transplant recipients?Prophylaxis of graft rejection in adults who have received a renal transplantMedDRA version: 17.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 100000004865

EUCTR2013-001178-20-NLppsale University Hospital, MHT, Department of Nephrology105

已完成

4 期

Cardiovascular (CV) risk prediction and CV biomarkers in renal transplant recipients treated with belatacept compared to calcineurin inhibitors (CNI).;Open randomized 12 month study.cardiovascular risk during prophylaxis of graft rejection in renal transplant recipientscardiovascular risk while preventing rejection of kidney transplant1003843010057166

NL-OMON45007niversity Hospital Uppsala50

尚未招募

Unknown

cardiovascular risk prediction as per prakriti

CTRI/2024/05/067087Chaudhary Brahm Prakash ayurved Charak Sansthan

招募中

4 期

A clinical trial for Heart Disease Risk assessment and treatment of patients with high risk.

CTRI/2019/04/018723Dr Saurabha Nayak